B2M.md
... ...
@@ -1,5 +1,6 @@
1 1
2 2
# B2M
3
+
3 4
## Overview
4 5
5 6
The B2M (β2-microglobulin) gene plays a crucial role in the function of the major histocompatibility complex (MHC) class I molecules, which are essential for immune system recognition of infected or malignant cells. B2M mutations in B-cell lymphomas, particularly in DLBCL and PMBCL, lead to reduced MHC class I expression, enabling tumor cells to evade immune detection and destruction by cytotoxic T cells.
... ...
@@ -8,10 +9,9 @@ The B2M (β2-microglobulin) gene plays a crucial role in the function of the maj
8 9
9 10
|Entity|Tier|Description |
10 11
|:------:|:----:|---------------------------------------|
11
-|BL |2 |relevance in BL not firmly established |
12
-|DLBCL |1 |high-confidence DLBCL gene |
13
-|FL |1 |high-confidence FL gene |
14
-|MCL |2 |relevance in MCL not firmly established|
12
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
13
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
14
+|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established|
15 15
16 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 17
BACH2.md
... ...
@@ -6,7 +6,7 @@ Mutations in this gene were first described in BL in 2019 by Grande et al.<sup>1
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------------------|
9
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
9
+|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
10 10
11 11
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
12 12
BCL11A.md
... ...
@@ -6,8 +6,7 @@ BCL11A (B-cell lymphoma/leukemia 11A) is a transcription factor involved in the
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------------------|
9
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
10
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
9
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
11 10
12 11
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
13 12
BCL2.md
... ...
@@ -7,9 +7,9 @@ BCL2 mutations are frequently found in DLBCL, particularly in the germinal cente
7 7
8 8
|Entity|Tier|Description |
9 9
|:------:|:----:|--------------------------------------|
10
-|BL |2 |relevance in BL not firmly established|
11
-|DLBCL |1-a |high-confidence DLBCL gene, hypermutated |
12
-|FL |1-a |high-confidence FL gene, hypermutated |
10
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
11
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a |high-confidence DLBCL gene, hypermutated |
12
+|![FL](images/icons/FL_tier1.png) |1-a |high-confidence FL gene, hypermutated |
13 13
14 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
15 15
BCL6.md
... ...
@@ -8,9 +8,9 @@ BCL6 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
8 8
9 9
|Entity|Tier|Description |
10 10
|:------:|:----:|--------------------------------------|
11
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
12
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
13
-|FL |1-a | aSHM target and high-confidence FL gene |
11
+|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
12
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
13
+|![FL](images/icons/FL_tier1.png) |1-a | aSHM target and high-confidence FL gene |
14 14
15 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16 16
BCOR.md
... ...
@@ -6,8 +6,8 @@ BCOR acts as a co-repressor of BCL6, and mutations in BCOR could impair its bind
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------|
9
-|DLBCL |1 |high-confidence DLBCL gene|
10
-|MCL |1 |high-confidence MCL gene |
9
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene|
10
+|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene |
11 11
12 12
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
13 13
BCR.md
... ...
@@ -4,16 +4,12 @@ BCR (Breakpoint Cluster Region Protein) is one of [a number of genes](https://gi
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
8
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
7
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
9 8
10 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
11 10
12 11
|Entity|source |frequency (%)|
13 12
|:------:|:---------------------:|:-------------:|
14
-|BL |GAMBL genomes+capture| 6.00 |
15
-|BL |Thomas cohort | 6.40 |
16
-|BL |Panea cohort |10.90 |
17 13
|DLBCL |GAMBL genomes | 4.97 |
18 14
|DLBCL |Schmitz cohort | 6.38 |
19 15
|DLBCL |Reddy cohort | 3.90 |
BIRC3.md
... ...
@@ -4,8 +4,8 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
8
-|MCL |1-a | aSHM target and high-confidence MCL gene |
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
8
+|![MCL](images/icons/MCL_tier1.png) |1-a | aSHM target and high-confidence MCL gene |
9 9
10 10
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
11 11
BLK.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
BMP7.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------|
7
-|BL |1 |high-confidence BL gene|
7
+|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
BRD4.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
BTG1.md
... ...
@@ -6,9 +6,9 @@ BTG1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------------------|
9
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
10
-|FL |1-a | aSHM target and high-confidence FL gene |
11
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
9
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
10
+|![FL](images/icons/FL_tier1.png) |1-a | aSHM target and high-confidence FL gene |
11
+|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
12 12
13 13
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
14 14
BTG2.md
... ...
@@ -6,9 +6,9 @@ BTG2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------------------|
9
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
10
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
11
-|FL |1-a | aSHM target and high-confidence FL gene |
9
+|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
10
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
11
+|![FL](images/icons/FL_tier1.png) |1-a | aSHM target and high-confidence FL gene |
12 12
13 13
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
14 14
BTK.md
... ...
@@ -5,8 +5,8 @@ One study reported BTK mutations in approximately 7% of FL and 11% of transforme
5 5
6 6
|Entity|Tier|Description |
7 7
|:------:|:----:|--------------------------|
8
-|DLBCL |1 |high-confidence DLBCL gene|
9
-|FL |1 |high-confidence FL gene |
8
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene|
9
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
10 10
11 11
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
12 12
C6orf27.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CAD.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CADPS2.md
... ...
@@ -7,7 +7,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
7 7
8 8
|Entity|Tier|Description |
9 9
|:------:|:----:|-----------------------------------------|
10
-|DLBCL |2 |relevance in DLBCL not firmly established|
10
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
11 11
12 12
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
13 13
CARD4.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CCDC42BPB.md
... ...
@@ -7,7 +7,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.<
7 7
8 8
|Entity|Tier|Description |
9 9
|:------:|:----:|--------------------------------------|
10
-|FL |2 |relevance in FL not firmly established|
10
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
11 11
12 12
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
13 13
CCL4.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2 |relevance in DLBCL not firmly established|
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CD74.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CD79B.md
... ...
@@ -6,9 +6,9 @@ CD79B mutations significantly contribute to the pathogenesis of DLBCL by enhanci
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------------------|
9
-|BL |2 |relevance in BL not firmly established|
10
-|DLBCL |1 |high-confidence DLBCL gene |
11
-|FL |2 |relevance in FL not firmly established|
9
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
10
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
11
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
12 12
13 13
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
14 14
CD83.md
... ...
@@ -11,9 +11,9 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al<sup>
11 11
12 12
|Entity|Tier|Description |
13 13
|:------:|:----:|--------------------------------------|
14
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
15
-|FL |1-a | aSHM target and high-confidence FL gene |
16
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
14
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
15
+|![FL](images/icons/FL_tier1.png) |1-a | aSHM target and high-confidence FL gene |
16
+|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
17 17
18 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 19
CDH17.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CDH8.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|---------------------------------------|
7
-|MCL |2 |relevance in MCL not firmly established|
7
+|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CIITA.md
... ...
@@ -6,7 +6,7 @@ CIITA encodes the major histocompatibility complex (MHC) class II transactivator
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------|
9
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene|
9
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene|
10 10
11 11
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
12 12
CNOT2.md
... ...
@@ -7,7 +7,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
7 7
8 8
|Entity|Tier|Description |
9 9
|:------:|:----:|-----------------------------------------|
10
-|DLBCL |2 |relevance in DLBCL not firmly established|
10
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
11 11
12 12
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
13 13
CNTNAP5.md
... ...
@@ -6,7 +6,7 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al.<sup
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|-----------------------------------------|
9
-|DLBCL |2 |relevance in DLBCL not firmly established|
9
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
10 10
11 11
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
12 12
COL11A1.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|---------------------------------------|
7
-|MCL |2 |relevance in MCL not firmly established|
7
+|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -35,3 +35,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
35 35
## COL11A1 Expression
36 36
![image](images/gene_expression/COL11A1_by_pathology.svg)
37 37
<!-- ORIGIN: zhangGenomicLandscapeMantle2014 -->
38
+<!-- MCL: zhangGenomicLandscapeMantle2014 -->
COL16A1.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|---------------------------------------|
7
-|MCL |2 |relevance in MCL not firmly established|
7
+|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -35,3 +35,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
35 35
## COL16A1 Expression
36 36
![image](images/gene_expression/COL16A1_by_pathology.svg)
37 37
<!-- ORIGIN: zhangGenomicLandscapeMantle2014 -->
38
+<!-- MCL: zhangGenomicLandscapeMantle2014 -->
COL4A2.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
COQ7.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2 |relevance in DLBCL not firmly established|
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
CPNE8.md
... ...
@@ -7,7 +7,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.<
7 7
8 8
|Entity|Tier|Description |
9 9
|:------:|:----:|--------------------------------------|
10
-|FL |2 |relevance in FL not firmly established|
10
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
11 11
12 12
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
13 13
CPXM2.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -37,3 +37,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
37 37
## CPXM2 Expression
38 38
![image](images/gene_expression/CPXM2_by_pathology.svg)
39 39
<!-- ORIGIN: burkhardtClinicalRelevanceMolecular2022b -->
40
+<!-- BL: burkhardtClinicalRelevanceMolecular2022b -->
CREBBP.md
... ...
@@ -6,9 +6,9 @@ CREBBP mutations are highly prevalent in both DLBCL and FL. These mutations ofte
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------------------|
9
-|DLBCL |1 |high-confidence DLBCL gene |
10
-|FL |1 |high-confidence FL gene |
11
-|BL |2 |association with BL is tenuous|
9
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
10
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
11
+|![BL](images/icons/BL_tier2.png) |2 |association with BL is tenuous|
12 12
13 13
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
14 14
... ...
@@ -80,3 +80,8 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
80 80
## CREBBP Expression
81 81
![image](images/gene_expression/CREBBP_by_pathology.svg)
82 82
<!-- ORIGIN: pasqualucciInactivatingMutationsAcetyltransferase2011a -->
83
+<!-- FL: pasqualucciInactivatingMutationsAcetyltransferase2011a -->
84
+<!-- BL: loveGeneticLandscapeMutations2012 -->
85
+<!-- BL: loveGeneticLandscapeMutations2012 -->
86
+<!-- DLBCL: pasqualucciInactivatingMutationsAcetyltransferase2011a -->
87
+<!-- MZL: parryWholeExomeSequencing2013 -->
CRIP1.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2 |relevance in DLBCL not firmly established|
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -38,3 +38,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
38 38
## CRIP1 Expression
39 39
![image](images/gene_expression/CRIP1_by_pathology.svg)
40 40
<!-- ORIGIN: chapuyMolecularSubtypesDiffuse2018b -->
41
+<!-- DLBCL: chapuyMolecularSubtypesDiffuse2018b -->
CTCF.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -37,3 +37,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
37 37
## CTCF Expression
38 38
![image](images/gene_expression/CTCF_by_pathology.svg)
39 39
<!-- ORIGIN: paneaWholeGenomeLandscape2019 -->
40
+<!-- BL: paneaWholeGenomeLandscape2019 -->
CTNNA2.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|---------------------------------------|
7
-|MCL |2 |relevance in MCL not firmly established|
7
+|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -35,3 +35,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
35 35
## CTNNA2 Expression
36 36
![image](images/gene_expression/CTNNA2_by_pathology.svg)
37 37
<!-- ORIGIN: zhangGenomicLandscapeMantle2014 -->
38
+<!-- MCL: zhangGenomicLandscapeMantle2014 -->
CTSS.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------|
7
-|FL |1 |high-confidence FL gene|
7
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -40,3 +40,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
40 40
## CTSS Expression
41 41
![image](images/gene_expression/CTSS_by_pathology.svg)
42 42
<!-- ORIGIN: barariaCathepsinAlterationsInduce2020c -->
43
+<!-- FL: barariaCathepsinAlterationsInduce2020c -->
CXCR4.md
... ...
@@ -11,9 +11,9 @@ Mutations in this gene were first described in DLBCL in 2012 by Khodabakhshi et
11 11
12 12
|Entity|Tier|Description |
13 13
|:------:|:----:|--------------------------------------|
14
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene |
15
-|FL |2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
16
-|BL |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
14
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene |
15
+|![FL](images/icons/FL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
16
+|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous |
17 17
18 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 19
CXCR5.md
... ...
@@ -6,7 +6,7 @@ CXCR5 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
6 6
7 7
|Entity|Tier|Description |
8 8
|:------:|:----:|--------------------------|
9
-|DLBCL |1-a | aSHM target and high-confidence DLBCL gene|
9
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene|
10 10
11 11
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
12 12
... ...
@@ -45,3 +45,5 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
45 45
## CXCR5 Expression
46 46
![image](images/gene_expression/CXCR5_by_pathology.svg)
47 47
<!-- ORIGIN: schmitzGeneticsPathogenesisDiffuse2018a -->
48
+<!-- PMBL: mottokIntegrativeGenomicAnalysis2019b -->
49
+<!-- DLBCL: schmitzGeneticsPathogenesisDiffuse2018a -->
CYB5D1.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
7
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -37,3 +37,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C
37 37
## CYB5D1 Expression
38 38
![image](images/gene_expression/CYB5D1_by_pathology.svg)
39 39
<!-- ORIGIN: loveGeneticLandscapeMutations2012 -->
40
+<!-- BL: loveGeneticLandscapeMutations2012 -->
EPPK1.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------|
7
-|BL |1 |high-confidence BL gene|
7
+|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -43,3 +43,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/E
43 43
## EPPK1 Expression
44 44
![image](images/gene_expression/EPPK1_by_pathology.svg)
45 45
<!-- ORIGIN: paneaWholeGenomeLandscape2019 -->
46
+<!-- BL: paneaWholeGenomeLandscape2019 -->
FUBP1.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2 |relevance in DLBCL not firmly established|
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -44,3 +44,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/F
44 44
## FUBP1 Expression
45 45
![image](images/gene_expression/FUBP1_by_pathology.svg)
46 46
<!-- ORIGIN: reddyGeneticFunctionalDrivers2017 -->
47
+<!-- DLBCL: reddyGeneticFunctionalDrivers2017 -->
IKBKB.md
... ...
@@ -4,7 +4,7 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|-----------------------------------------|
7
-|DLBCL |2 |relevance in DLBCL not firmly established|
7
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
8 8
9 9
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
10 10
... ...
@@ -37,4 +37,7 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/I
37 37
![image](images/proteinpaint/IKBKB.svg)
38 38
## IKBKB Expression
39 39
![image](images/gene_expression/IKBKB_by_pathology.svg)
40
-<!-- ORIGIN: reddyGeneticFunctionalDrivers2017 -->
40
+<!-- ORIGIN: rossiAlterationBIRC3Multiple2011a -->
41
+<!-- MZL: rossiAlterationBIRC3Multiple2011a -->
42
+<!-- DLBCL: reddyGeneticFunctionalDrivers2017 -->
43
+<!-- PMBL: wienandGenomicAnalysesFlowsorted2019b -->
MYD88.md
... ...
@@ -4,9 +4,8 @@
4 4
5 5
|Entity|Tier|Description |
6 6
|:------:|:----:|--------------------------------------|
7
-|BL |2 |relevance in BL not firmly established|
8
-|DLBCL |1 |high-confidence DLBCL gene |
9
-|FL |2 |relevance in FL not firmly established|
7
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
8
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
10 9
11 10
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
12 11
... ...
@@ -48,4 +47,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/M
48 47
![image](images/proteinpaint/MYD88.svg)
49 48
## MYD88 Expression
50 49
![image](images/gene_expression/MYD88_by_pathology.svg)
51
-<!-- ORIGIN: ngoOncogenicallyActiveMYD882011a -->
50
+<!-- ORIGIN: yanBCRTLRSignaling2012a -->
51
+<!-- DLBCL: ngoOncogenicallyActiveMYD882011a -->
52
+<!-- MZL: yanBCRTLRSignaling2012a -->